Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2, SAAVI MVA-C and Novartis Subtype C gp140 With MF59 Adjuvant in Various Vaccination Schedules in HIV-uninfected Healthy Vaccinia-naïve Adult Participants in South Africa

NCT01418235 is registered in ClinicalTrials.gov with HIV Vaccine Trials Network as lead sponsor.

NCT NCT01418235
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01418235 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1 Placebo-controlled Clinical Trial to Evaluate the Safety and Immunogenicity of SAAVI DNA-C2, SAAVI MVA-C and Novartis Subtype C gp140 With MF59 Adjuvant in Various Vaccination Schedules in HIV-uninfected Healthy Vaccinia-naïve Adult Participants in South Africa
Lead sponsor
HIV Vaccine Trials Network
Phase
Phase 1
Overall status
Completed
Start date
December 19, 2011
Completion date
December 9, 2015
Enrollment
184 (actual)
Sites
3

Conditions

As the registry lists them; a condition with its own page is linked.

hiv preventive vaccine, hiv seronegativity